IntraBio

IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort businesswire.com/news/home/2024…

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) accesswire.com/660477/IntraBi…

IntraBio Appoints Jim Meyers as President and CEO accesswire.com/618176/IntraBi…

Professor Michael Strupp Receives the 2020 Galenus-von-Pergamon Award accesswire.com/viewarticle.as…

IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.as…

New hope for Treatment Against Niemann-Pick disease Type C businessnewstribune.com/2020/10/15/new… via @Business News Tribune

"IntraBio Reports Positive Data from NPC Study" - @GlobalGenes globalgenes.org/2020/10/06/int…

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C accesswire.com/viewarticle.as…

JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: bit.ly/2KYdOvD #NPC #niemannpick #nnpdf

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease #IntraBio #Ataxia #FDA #Biotech accesswire.com/538752/IntraBi…

IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease #IntraBio #MHRA #NPC accesswire.com/538583/IntraBi…

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease #Biotech #FDA #IntraBio #IND accesswire.com/535211/IntraBi…

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease #Biotech #FDA #IntraBio accesswire.com/534958/IntraBi…

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation for IB4000 #RareDisease #Biotech #IntraBio accesswire.com/532110/IntraBi…

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB4000 #RareDisease #FDA #Biotech #IntraBio accesswire.com/530834/IntraBi…

IntraBio Receives Tay-Sachs and Sandhoff Rare Pediatric Disease Designation from the FDA #RareDisease #Biotech #IntraBio accesswire.com/530328/IntraBi…

RareDaily reports on our recent Rare Pediatric Disease Designation for Niemann-Pick disease Type C for our lead compound series globalgenes.org/raredaily/fda-… via @GlobalGenes

IntraBio Receives Spinocerebellar Ataxia Orphan Drug Designation from the FDA #IntraBio #Ataxia #RareDisease #Biotech accesswire.com/530119/IntraBi…

IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of Spinocerebellar Ataxia #RareDisease #Ataxia #IntraBio accesswire.com/529750/IntraBi…

IntraBio Receives Niemann-Pick Disease Rare Pediatric Disease Designation from the FDA for IB1000 Series #RareDisease #OrphanDisease #Biotech #NiemannPick #FDA #IntraBio accesswire.com/529563/IntraBi…